3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
211
Recurrence
27
Neoplasms, Plasma Cell
15
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Myeloid, Acute
9
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Smoldering Multiple Myeloma
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Hematologic Neoplasms
4
Plasmacytoma
3
Paraproteinemias
3
Myelodysplastic Syndromes
3
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Diseases
3
Carcinoma, Non-Small-Cell Lung
3
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Plasmablastic Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Interventions
venetoclax
6
fludarabine phosphate
5
Dexamethasone
4
ibrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
pomalidomide
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
pirtobrutinib
1
pembrolizumab
1
obinutuzumab
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
auricularum
1
acalabrutinib
1
Sirolimus
1
RG7388
1
Nivolumab
1
Maintenance
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Chromosome 17 deletion
×
daratumumab
×
Clear all
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled